The history of synthetic peptide chemistry is not a continuous narrative of incremental progress but a series of discrete technical inflection points, each of which expanded the structural complexity of accessible peptide targets and ultimately enabled the current pipeline of approved peptide therapeutics — a class now generating over $50 billion annually in pharmaceutical revenues.
Foundation: Fischer's Solution Chemistry and the Peptide Bond (1901–1930s)
Emil Fischer's identification of the peptide bond linkage (1901) and subsequent synthesis of polypeptide chains via carboxyl activation established the conceptual framework for synthetic peptide chemistry. However, solution-phase synthesis of longer peptides suffered from racemization at each coupling step, poor yields in multistep sequences, and the practical impossibility of purifying intermediates efficiently. Fischer's work defined the scientific question; it did not provide a scalable answer. The interwar period saw incremental improvements in protecting group chemistry (carbobenzoxy group by Bergmann and Zervas, 1932) and coupling reagents, but full-length bioactive peptide synthesis remained prohibitively laborious through the 1950s.
Du Vigneaud and the First Synthetic Bioactive Peptide (1953)
Vincent du Vigneaud's total synthesis of oxytocin (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂, MW 1,007 Da) in 1953 — awarded the Nobel Prize in Chemistry in 1955 — marked the first demonstration that a biologically active peptide hormone could be chemically reproduced with full activity. This was performed by solution-phase methods over multiple steps, requiring selective disulfide bond formation. The synthesis confirmed that primary sequence alone determines biological activity — a finding that validated the entire enterprise of synthetic peptide pharmacology and laid the conceptual groundwork for what followed.
Merrifield's Solid-Phase Peptide Synthesis Revolution (1963)
R. Bruce Merrifield's introduction of solid-phase peptide synthesis (SPPS) in 1963 (Nobel Prize in Chemistry, 1984) fundamentally changed the accessibility of synthetic peptides. By anchoring the C-terminal residue to an insoluble polystyrene resin and building the chain sequentially using Boc/Bzl protection chemistry, Merrifield eliminated intermediate isolation steps, enabled automation, and reduced synthesis time for a decapeptide from months to days. The subsequent development of Fmoc/tBu chemistry by Carpino and Han (1972) provided base-labile N-terminal protection compatible with acid-labile side-chain deprotection, allowing milder cleavage conditions and access to a wider residue scope including acid-sensitive sequences. Modern automated synthesizers execute coupling cycles in 10–30 minutes per residue, enabling 30-residue peptides in 24–48 hours with coupling efficiencies exceeding 99.5% per step (measured by ninhydrin or quantitative Fmoc release).
From Research Tools to Approved Therapeutics: Cyclosporin A, Insulin Analogues, and the GLP-1 Agonist Era (1980–2023)
The regulatory approval of synthetic salmon calcitonin (1975), cyclosporin A (1983), and human insulin analogues (1996–2000) demonstrated that synthetic peptides could achieve regulatory quality standards. The critical inflection came with the GLP-1 receptor agonist program: exenatide (Byetta, AZ/Eli Lilly, FDA 2005), a 39-residue Gila monster venom-derived peptide with DPP-4 resistance at position 2 (His-Gly instead of His-Ala), established GLP-1R agonism as a viable therapeutic mechanism. Liraglutide (Victoza, Novo Nordisk, FDA 2010) introduced fatty acid conjugation for albumin binding (t½ ~13 h). Semaglutide (Ozempic, FDA 2017; Wegovy, FDA 2021) refined this to C18 fatty diacid with linker, achieving weekly dosing (t½ ~165 h). Tirzepatide (Mounjaro, FDA 2022) introduced dual GIP/GLP-1 receptor agonism in a single 39-residue molecule, with Phase 3 data demonstrating 22.5% mean body weight reduction at 15 mg/week (SURMOUNT-1, N=2,539, p<0.001). Retatrutide, a triple GLP-1R/GIPR/GCGR agonist, is demonstrating 24.2% weight reduction at 12 mg/week in Phase 2 data — representing the current frontier of incretin-axis peptide pharmacology.
Alpha Nordisk presents this content for research documentation purposes. All products referenced are for research and laboratory use only. Not for unsupervised human consumption.